Sign in

Private company

CTI BioPharma

Logo: Bisvictor, CC BY-SA 4.0, via Wikimedia Commons4

Pharmaceutical company based in Seattle, USA, founded in 20141

In its 2023 annual report the company says: “We are a commercial biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers where there is a significant unmet medical need.”68

Last updated Oct 21, 2026.

Overview

2014Founded1
  • IndustryPharmaceutical Preparations1
  • HeadquartersSeattle1
  • Websitewww.ctibiopharma.com
  • Legal formpublic company1
  • Incorporated inDE5
  • Business address3101 Western Avenue, Suite 800, Seattle, Wa 981215
  • Filer categoryNon-accelerated filer, Smaller reporting company5
  • LEI549300RJTND7CT8R88533
  • StatusActive3
  • LEI statusLapsed (not renewed)3
  • Registered addressC/O CT Corporation System, 98501 Olympia, United States3
  • Registered withCorporations Division (Office of the Secretary of State), 6013390383

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-147.9%Operating margin6
-172.4%Net margin6

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Cost of revenue3¢$3.5M
  • Selling, general and admin84¢$84.8M
  • Interest13¢$13.1M

Out of $53.9M in revenue.6 The company lost money this year.

Financial statements

Revenue789106$53.9M in 2022−6% since 2016
0$20.0M$40.0M$60.0M2016: $57.4M$57.4M20162017: $25.1M$25.1M2017−56%2018: $26.3M$26.3M2018+5%2019: $3.3M$3.3M2019−87%2020: $0$020202021: $0$020212022: $53.9M$53.9M2022
Operating income78910116-$79.8M in 2022+62% since 2016
-$100.0M-$75.0M-$50.0M-$25.0M02016: -$49.2M-$49.2M20162017: -$39.5M-$39.5M2017−20%2018: -$32.9M-$32.9M2018−17%2019: -$40.7M-$40.7M2019+24%2020: -$47.8M-$47.8M2020+17%2021: -$95.3M-$95.3M2021+100%2022: -$79.8M-$79.8M2022−16%
Net income78910116-$93.0M in 2022+79% since 2016
-$100.0M-$75.0M-$50.0M-$25.0M02016: -$52.0M-$52.0M20162017: -$40.7M-$40.7M2017−22%2018: -$29.3M-$29.3M2018−28%2019: -$40.0M-$40.0M2019+36%2020: -$52.5M-$52.5M2020+31%2021: -$97.9M-$97.9M2021+87%2022: -$93.0M-$93.0M2022−5%
Fiscal year2016201720182019202020212022
Revenue$57.4M7$25.1M8$26.3M9$3.3M10$010$06$53.9M6
Cost of revenue$1.4M7$364.0K8$879.0K8$06$3.5M6
Selling, general and admin$45.3M7$31.4M8$22.1M9$19.2M10$17.6M11$56.2M6$84.8M6
Operating expenses$95.3M6$133.7M6
Operating income-$49.2M7-$39.5M8-$32.9M9-$40.7M10-$47.8M11-$95.3M6-$79.8M6
Interest$2.6M7$1.9M8$1.2M9$1.0M10$828.0K11$2.4M6$13.1M6
Net income-$52.0M7-$40.7M8-$29.3M9-$40.0M10-$52.5M11-$97.9M6-$93.0M6
Earnings per share-$0.7411-$1.096-$0.816
Earnings per share (diluted)-$0.7411-$1.096-$0.816
Shares (weighted, basic)90.1M shares6114.7M shares6
Shares (weighted, diluted)90.1M shares6114.7M shares6

Compare CTI BioPharma with another company

Corporate structure

CTI BioPharma sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of CTI BioPharma

  • CTI BioPharma Seattle, Washington, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What CTI BioPharma reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$2.4M6 Dec 31, 2022$5.7M6 Dec 31, 2021−59.0%
Accumulated depreciation$2.4M6 Dec 31, 2022$5.6M6 Dec 31, 2021−57.7%
Property and equipment, net$06 Dec 31, 2022$176.0K6 Dec 31, 2021−100.0%
Operating-lease assets (leased space)$2.1M6 Dec 31, 2022$3.1M6 Dec 31, 2021−33.2%

Real estate and locations

ItemLatestA year beforeChange
Area of real estate44,000 sq ft6 Apr 30, 202244,000 sq ft11 Dec 31, 20170%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$30.4M6 Dec 31, 2022$65.4M6 Dec 31, 2021−53.5%
Marketable securities, current$49.5M6 Dec 31, 2022$06 Dec 31, 2021

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$23.2M6 Dec 31, 2022$06 Dec 31, 2021

Inventory

ItemLatestA year beforeChange
Inventory, total$733.0K6 Dec 31, 2022$06 Dec 31, 2021
Raw materials$156.0K6 Dec 31, 2022$06 Dec 31, 2021
Work in process$496.0K6 Dec 31, 2022$06 Dec 31, 2021
Finished goods$81.0K6 Dec 31, 2022$06 Dec 31, 2021

Leadership

Who has led CTI BioPharma, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. James A. Bianco2006–2016
  2. Richard L. Love2016
  3. Adam R. Craig2017–2023

President

  1. James A. Bianco2006–2016
  2. Craig Philips2008–2012
  3. Richard L. Love2016
  4. Adam R. Craig2017–2023

Chief financial officer

  1. David Kirske2017–2023

Chief operating officer

  1. Bruce J. Seeley2017–2022
2010201520202025
Board members and other officers (28)

Former names

  • CELL THERAPEUTICS INCJun 28, 1996 to May 29, 20145

Timeline

  1. Jun 26, 20238-K Ended a material agreement; Completed an acquisition or sale; Debt or obligation accelerated46
  2. May 30, 20238-K Other events47
  3. May 10, 20238-K Entered a material agreement; Bylaws or fiscal year changed; Other events48
  4. Mar 6, 20238-K Results of operations49
  5. Nov 7, 20228-K Results of operations50
  6. Oct 13, 20228-K Executive or director change51
  7. Sep 28, 20228-K Other events52
  8. Aug 15, 20228-K Other events53
  9. Aug 8, 20228-K Results of operations54
  10. Jun 3, 20228-K Executive or director change; Shareholder vote55
  11. May 12, 20228-K Results of operations56
  12. Mar 31, 20228-K Results of operations57
  13. Oct 3, 2017New chief executive Adam R. Craig becomes CEO15
  14. Oct 24, 2016New chief executive Richard L. Love becomes CEO16
  15. 2014Founded Founded1
  16. Jan 5, 2006New chief executive James A. Bianco becomes CEO17

Calendar

When it reported results

  1. Mar 6, 2023Reported quarterly or annual results49
  2. Nov 7, 2022Reported quarterly or annual results50
  3. Aug 8, 2022Reported quarterly or annual results54
  4. May 12, 2022Reported quarterly or annual results56
  5. Mar 31, 2022Reported quarterly or annual results57
  6. Mar 2, 2022Reported quarterly or annual results58

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

212 filings to the SEC since October 2021: 2 annual reports, 5 quarterly reports, 14 major events, 52 insider forms, 15 large holders, 124 other. The latest 20:

  1. Jul 6, 202315-12G EDGAR
  2. Jun 29, 2023EFFECT EDGAR
  3. Jun 29, 2023EFFECT EDGAR
  4. Jun 29, 2023EFFECT EDGAR
  5. Jun 29, 2023EFFECT EDGAR
  6. Jun 29, 2023EFFECT EDGAR
  7. Jun 29, 2023EFFECT EDGAR
  8. Jun 29, 2023EFFECT EDGAR
  9. Jun 29, 2023EFFECT EDGAR
  10. Jun 29, 2023EFFECT EDGAR
  11. Jun 29, 2023EFFECT EDGAR
  12. Jun 29, 2023EFFECT EDGAR
  13. Jun 29, 2023EFFECT EDGAR
  14. Jun 29, 2023EFFECT EDGAR
  15. Jun 29, 2023EFFECT EDGAR
  16. Jun 29, 2023EFFECT EDGAR
  17. Jun 29, 2023EFFECT EDGAR
  18. Jun 29, 2023EFFECT EDGAR
  19. Jun 29, 2023EFFECT EDGAR
  20. Jun 29, 2023EFFECT EDGAR

The 212 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

30 open-market trades by officers, directors and large owners since October 2021: 2 buys and 28 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jan 24, 2023Craig Adam RPresident and CEOSale85,317$6.00$511.9KForm 4
Jan 24, 2023Fong James KEVP & Chief Commercial OfficerSale100,000$6.00$600.0KForm 4
Jan 3, 2023Craig Adam RPresident and CEOSale84,683$6.01$508.9KForm 4
Jan 3, 2023KIRSKE DAVIDEVP, Chief Financial OfficerSale27,021$6.01$162.4KForm 4
Dec 30, 2022Craig Adam RPresident and CEOSale17,100$6.00$102.7KForm 4
Dec 30, 2022KIRSKE DAVIDEVP, Chief Financial OfficerSale13,847$6.00$83.1KForm 4
Dec 29, 2022Craig Adam RPresident and CEOSale13,800$6.00$82.8KForm 4
Dec 29, 2022KIRSKE DAVIDEVP, Chief Financial OfficerSale13,174$6.00$79.0KForm 4
Nov 10, 2022Craig Adam RPresident and CEOSale188,304$6.00$1.1MForm 4
Nov 9, 2022Craig Adam RPresident and CEOSale53,996$6.00$324.1KForm 4
Nov 8, 2022Metzger Michael ADirectorSale91,500$5.59$511.2KForm 4
Oct 4, 2022KIRSKE DAVIDEVP, Chief Financial OfficerSale2,109$6.26$13.2KForm 4
Oct 3, 2022KIRSKE DAVIDEVP, Chief Financial OfficerSale300$6.25$1.9KForm 4
Sep 30, 2022KIRSKE DAVIDEVP, Chief Financial OfficerSale139,841$6.05$846.0KForm 4
Sep 29, 2022KIRSKE DAVIDEVP, Chief Financial OfficerSale900$6.00$5.4KForm 4
Sep 16, 2022KIRSKE DAVIDEVP, Chief Financial OfficerSale22,592$6.02$136.0KForm 4
Sep 12, 2022Craig Adam RPresident and CEOSale242,300$6.43$1.6MForm 4
Aug 16, 2022Craig Adam RPresident and CEOBuy5,000$5.50$27.5KForm 4
Aug 9, 2022LAMPERT MARK NDirectorSale8,500,000$6.12$52.0MForm 4
Jul 7, 2022Metzger Michael ADirectorSale20,121$6.51$131.0KForm 4

All 30 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How CTI BioPharma is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARCTI BIOPHARMA CORP2
  • CIK0000891293
  • Employer ID (EIN)91-15339122
  • Filer statusNon-accelerated filer<br>smaller reporting company2
  • Incorporated inDelaware2
  • Fiscal year endsDecember 312
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • Business address3101 Western Avenue, Suite 800, Seattle, WA 981212
  • Phone20628271002
  • Shares outstanding131,880,176 as of May 4, 202314
  • Public float$625.7M as of Jun 30, 20226
  • On EDGAR sinceJun 27, 19962
  • Filings2,393 in all: 4 (784), 8-K (574), 10-Q (81), DEFA14A (79), SC 13G/A (66), EFFECT (60), 424B5 (57), SC 13G (49)2
    All 68 form types

    POS AM (48), S-8 POS (37), S-3 (36), DEF 14A (35), 3 (32), 424B3 (32), UPLOAD (31), 10-K (27), CT ORDER (27), S-8 (27), 4/A (26), CORRESP (25), PRE 14A (25), 425 (24), 8-K/A (21), S-3/A (19), SC 13D/A (18), SC TO-I/A (16), 5 (12), 10-K/A (10), FWP (10), 424B7 (9), 424B2 (8), ARS (7), SC 13D (7), 10-Q/A (5), S-4/A (5), SC 14D9/A (5), 8-A12G/A (4), RW (4), SC TO-C (4), SC TO-T/A (4), PRER14A (3), 10-12G/A (2), 8-A12B (2), 8-A12B/A (2), D (2), DEFR14A (2), DEFS14A (2), NT 10-Q (2), PRES14A (2), S-1/A (2), S-3ASR (2), S-4 (2), SC TO-I (2), SC14D9C (2), 15-12B (1), 15-12G (1), 25-NSE (1), 3/A (1), 424B4 (1), 8-A12G (1), NT 10-K (1), POS462B (1), POSASR (1), REGDEX (1), S-1 (1), S-3MEF (1), SC 14D9 (1), SC TO-T (1)

  • Latest filingsAnnual report (10-K) Mar 6, 2023
    Quarterly report (10-Q) May 15, 2023
    Proxy statement (DEF 14A) Apr 28, 2023
    Latest 8-K (8-K) Jun 26, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
    SEC EDGAROther events
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
    SEC EDGAROther events
  53. 53
    SEC EDGAROther events
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68